Suchergebnisse - "Hoefsmit, E. P."

PubPharm (4)

1

Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma

enthalten in: Cancer immunology, immunotherapy : CII | 2024

von Versluis, J. | Hoefsmit, E. | Shehwana, H. | +4

2

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Schmitt, C. | Hoefsmit, E. | Fangmeier, T. | +15

3

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections

enthalten in: Cancer immunology immunotherapy | 2023

von Schmitt, C. | Hoefsmit, E. | Fangmeier, T. | +15

4

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

enthalten in: Nature medicine | 2021

von Rozeman, E. | Hoefsmit, E. | Reijers, I. | +31

CommentIn: Nat Rev Clin Oncol. 2021 Apr;18(4):193. - PMID 33627793

1
[1]